Oncoceutics competitors and similar companiesClear all
Oncoceutics's competitors and similar companies include Deciphera Pharmaceuticals and Ablynx.
 Oncoceutics Oncoceutics is a drug discovery and development company focused on selective G protein-coupled receptor antagonists for oncology.
|  Deciphera Pharmaceuticals Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer. |  Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. | |
Founding Date | Founding Date 2009 | Founding Date 2003 | Founding Date 2001 |
Type | Type Subsidiary | Type Public | Type Subsidiary |
Tags | |||
Locations | Locations Philadelphia, US HQ | Locations Waltham, US HQ Lawrence, US | Locations Gent, BE HQ |
Employees | Employees 12 | Employees 35037% increase | Employees 2681% decrease |
Twitter followers | Twitter followers 313 | Twitter followers 750 | Twitter followers 284 |
Employee Rating | Employee Rating 5 | Employee Rating 3.7 | Employee Rating 3.3 |
Financial | |||
Revenue (est.) | Revenue (est.) $5.2m (FY, 2019) | Revenue (est.) N/A | Revenue (est.) €85.2m (FY, 2016) |
Net income | Net income ($3.7m) (FY, 2019) | Net income ($25.9m) (FY, 2016) | Net income (€1.1m) (FY, 2016) |
Operating ⚠ | |||
Patents (Foreign) | Patents (Foreign) N/A | Patents (Foreign) 47 (Aug, 2017) | Patents (Foreign) 180 (Q2, 2017) |
Patents (US) | Patents (US) N/A | Patents (US) 11 (Aug, 2017) | Patents (US) 50 (Q2, 2017) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 714m | Total funding raised $ 498.8m |
For sources of this data, please see the company profile
View company profiles
Deciphera Pharmaceuticals
HQ
Waltham, US
Employees
350↑ 37% increase
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company that develops medicines for patients with cancer.
View companyAblynx
HQ
Gent, BE
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments.
View company